you are viewing a single comment's thread.
agree mCRC data are very important. At the same time, MARQUEE data are critical to see what went wrong and whether the management is capable of leading.
If data is good and management is bad then the company must be sold. Amylin is a good example.
Therefore, let us and medical community see the MARQUEE and mCRC data. If the data are promising a company like AMGN can take from there. They will be more than willing to buy out ARQL Jap partners.